Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

DTC Guidances Could Limit Use Of Celebrity Endorsers Outside Of Product Ads

  • News

Executive Summary

Manufacturers may need to reevaluate their use of celebrity endorsers in light of FDA's draft DTC guidances to ensure that disease awareness ads are distinct from product-specific ads

You may also be interested in...



Vioxx Withdrawal Fuels Criticism Of DTC; Liability Exposure May Be Test

The Vioxx withdrawal will prompt renewed debate over DTC advertising

Vioxx Withdrawal Fuels Criticism Of DTC; Liability Exposure May Be Test

The Vioxx withdrawal will prompt renewed debate over DTC advertising

Disease Awareness Ad Guidance Stresses Need For “Distinct” Messages

The impact of FDA's draft guidance on disease awareness ads will depend upon how willing manufacturers are to allot portions of their advertising budgets to non-branded ads

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

EU Multistakeholder Project Aims To Give eConsent The ‘Place It Deserves’

EU Regulatory Reforms Mean Many Orphan Drug Producers Won’t Benefit From Incentives

Canada Proposes List Of ‘Critical Products’ & More Agile Regulation To Address Shortages

Third Time’s A Charm? US FDA Once Again Proposes Mandatory Consumer Rx Info

See All
UsernamePublicRestriction

Register

PS043611

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By